News for ICPT Stock

Intercept Announces New PBC Data Analyses to be Presented at Digestive Disease Week® 2024 Conference Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage at AASLD The Liver Meeting® 2023 Intercept Announces New Findings from Long-term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD The Liver Meeting® 2023 Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc. Alfasigma S.p.A. successfully completes tender offer for all outstanding shares of common stock of Intercept Pharmaceuticals, Inc. Alfasigma S.p.A. Announces Expiration of Hart-Scott-Rodino Waiting Period in Connection with Pending Acquisition of Intercept Pharmaceuticals, Inc. Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors Alfasigma S.p.A. Tender Offer for Intercept Pharmaceuticals, Inc. Commences Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases Intercept Pharmaceuticals to Conduct Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences Intercept Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Updates Intercept to Announce Second Quarter 2023 Financial Results on August 2, 2023 Intercept Announces Restructuring to Strengthen Focus on Rare and Serious Liver Diseases and Significantly Reduce Operating Expenses Intercept Presents New Data Showing Significant Impact of OCA-bezafibrate Combination on Normalization of Multiple Biomarkers of PBC-Induced Liver Damage Intercept Receives Complete Response Letter from FDA for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH Intercept Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC to be Featured in Podium Presentation at EASL Congress 2023 Intercept Pharmaceuticals to Conduct One-on-One Meetings with Investors at the Jefferies Healthcare Conference June 7-8, 2023 Intercept Announces Outcome of FDA Advisory Committee Meeting for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH Intercept Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Review Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH Intercept Pharmaceuticals Receives FDA Orphan Drug Designation for the Fixed-Dose Combination of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis (PBC) Intercept Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Update on Commercial Launch Strategy for NASH Intercept Announces New Data to be Presented at The European Association for the Study of the Liver (EASL) Congress 2023 and Provides Update on OCA-bezafibrate Fixed-Dose Combination (FDC) Development Program Intercept to Announce First Quarter 2023 Financial Results and Provide Update on Commercial Launch Strategy for NASH on April 27, 2023    Intercept Announces FDA Advisory Committee Meeting Date for Obeticholic Acid as a Treatment for Pre-Cirrhotic Liver Fibrosis due to NASH Intercept Pharmaceuticals to Conduct One-on-One Meetings with Investors at the Barclays Global Healthcare Conference March 14, 2023 Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates; Issues 2023 Financial Guidance Intercept Pharmaceuticals to Participate in Cowen’s 43rd Annual Health Care Conference on March 7, 2023  Intercept to Announce Fourth Quarter and Full Year 2022 Financial Results on March 2, 2023 FDA Accepts Intercept’s New Drug Application for OCA for the Treatment of Pre-Cirrhotic Liver Fibrosis Due to NASH Intercept Pharmaceuticals to Present at J.P. Morgan 41st Annual Healthcare Conference on January 12, 2023 Intercept Announces Efficacy and Safety Data from Phase 3 REGENERATE Study in Liver Fibrosis due to NASH to be Presented at NASH-TAG Conference 2023 Intercept Resubmits New Drug Application to U.S. FDA for Obeticholic Acid in Patients with Liver Fibrosis due to NASH New Study Published in The American Journal of Pathology Suggests Obeticholic Acid (OCA) May Improve Cognitive Impairment Associated with Cholestatic Liver Disease Intercept Pharmaceuticals to Participate in Piper Sandler’s 34th Annual Healthcare Conference on December 1, 2022  Komodo Health’s Real-World Evidence and Technology Platform Powers Two Real-World Analyses in Primary Biliary Cholangitis for Intercept Pharmaceuticals Intercept Announces Development Program for Next-Generation FXR Agonist INT-787 in Severe Alcohol-Associated Hepatitis Intercept Announces Additional Positive Data in Fibrosis due to NASH from New Analysis of Phase 3 REGENERATE Study at AASLD The Liver Meeting® 2022 Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting® 2022 Intercept Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update Intercept Announces New Data to be Presented in PBC, Liver Fibrosis due to NASH and Pipeline at AASLD The Liver Meeting® 2022 Intercept to Announce Third Quarter 2022 Financial Results on November 1, 2022 Intercept Pharmaceuticals to Participate in H.C. Wainwright’s 6th Annual NASH Investor Conference on October 17, 2022 Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid (OCA) in Compensated Cirrhosis due to NASH Did Not Meet its Primary Endpoint Intercept Pharmaceuticals Announces Summary of Key Actions in Strategic Financial Repositioning Improved Transplant-Free Survival Observed with Obeticholic Acid in People with PBC Published in Gastroenterology Intercept Pharmaceuticals to Conduct Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences Intercept Pharmaceuticals to Conduct One-on-One Meetings with Investors at the Citi 17th Annual BioPharma Conference September 8, 2022 Intercept Pharmaceuticals Announces Repurchase of Convertible Notes Intercept Pharmaceuticals to Participate in B. Riley’s PBC Symposium on August 24, 2022 Intercept Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update Intercept to Announce Second Quarter 2022 Financial Results on August 3, 2022 Intercept Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid (OCA) Intercept Announces Closing of Transaction with Advanz Pharma to Transfer Rights to Commercialize Ocaliva® for PBC Outside the U.S. Intercept Announces PBC Data Presentations at The International Liver Congress™ 2022 Intercept Provides Update on NASH Regulatory Timeline Intercept Announces New Clinical Trial and Real-World Outcomes Data for Ocaliva in PBC Intercept Announces First Patient Dosed in Phase 2 Study of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis Intercept Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update Intercept Announces Advanz Pharma to Acquire Ocaliva in PBC in Markets Outside the U.S. for up to $450MM, including $405MM Upfront and an Additional $45MM in Contingent Payments Intercept to Announce First Quarter 2022 Financial Results on May 6, 2022 Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results, Issues 2022 Financial Guidance and Provides Business Update Intercept to Announce Fourth Quarter and Full Year 2021 Financial Results on March 2, 2022 Intercept Pharmaceuticals Provides Update on Phase 3 REVERSE Trial in Compensated Cirrhosis Due to NASH Intercept Announces Withdrawal of EMA Marketing Authorization Application for Obeticholic Acid for Advanced Liver Fibrosis Due to NASH Intercept Announces New Long-Term Data Demonstrating Potential of Obeticholic Acid to Improve Transplant-Free Survival in Patients with PBC Intercept to Present at Upcoming Investor Conferences Intercept Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update Intercept Announces Late-Breaking Oral Presentation and Poster Presentations at The Liver Meeting Intercept to Announce Third Quarter 2021 Financial Results on November 3, 2021 Intercept to Present at the 2021 Cantor Virtual Global Healthcare Conference Intercept Pharmaceuticals Announces Convertible Notes Repurchase Intercept to Present at the Virtual Baird 2021 Global Healthcare Conference Intercept Pharmaceuticals Announces Convertible Notes Exchange, New Issuance and Stock Repurchase Intercept Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update Intercept to Announce Second Quarter 2021 Financial Results on July 29, 2021 Intercept to Present New NASH and PBC Data at the Digital International Liver Congress™ 2021 Intercept to Present at the Raymond James 2021 Human Health Innovation Conference Intercept Appoints M. Michelle Berrey, M.D., M.P.H., as President of Research & Development and Chief Medical Officer Intercept Appoints Andrew Saik as Chief Financial Officer Intercept to Present at the Jefferies Virtual Healthcare Conference Intercept Announces Updated Ocaliva® (obeticholic acid) U.S. Prescribing Information Intercept to Present at the 2021 RBC Capital Markets Global Healthcare Conference Intercept Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update Intercept to Announce First Quarter 2021 Financial Results on May 6, 2021 Intercept Announces Departure of Chief Financial Officer Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results, Issues 2021 Financial Guidance and Provides Business Update Intercept Appoints Dagmar Rosa-Bjorkeson to Its Board of Directors Intercept to Present at Upcoming Investor Conferences Intercept Appoints Linda Richardson as Chief Commercial Officer Intercept to Announce Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021 Intercept Company Statement on Analyst Note Intercept Appoints Jared M. Freedberg as General Counsel and Secretary Intercept to Present at the 39th Annual J.P. Morgan Healthcare Conference Intercept Pharmaceuticals Announces Leadership Transition Intercept to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference New Data from the Interim Analysis of REGENERATE Show OCA Improved Noninvasive Measures of Fibrosis in a Subgroup of High-Risk Patients with Fibrosis Due to NASH Intercept Pharmaceuticals Reports Third Quarter 2020 Financial Results, Announces Updates to Financial Guidance and Provides Business Update Intercept to Announce Third Quarter 2020 Financial Results on November 9, 2020 New PBC and NASH Data to be Presented at AASLD’s The Liver Meeting Digital Experience™ New Data from the Interim Analysis of REGENERATE Show that OCA Helped Patients with Liver Fibrosis Due to NASH Achieve Sustained Improvement in Noninvasive Markers of Fibrosis Over Two Years of Treatment Intercept to Present New NASH and PBC Data at the Digital International Liver Congress™ 2020 Intercept Pharmaceuticals Reports Second Quarter 2020 Financial Results, Announces Updates to Financial Guidance and Provides Business Update Intercept to Announce Second Quarter 2020 Financial Results on August 10, 2020 Intercept Provides Regulatory Update Intercept Receives Complete Response Letter from FDA for Obeticholic Acid for the Treatment of Fibrosis Due to NASH Intercept to Present at the Bank of America Merrill Lynch Virtual Global Healthcare Conference